Phase 3 Redemption Window Nears for Beaten-Down Neumora Shares

Neumora’s next meaningful upside catalyst is the joint Phase 3 KOASTAL-2/KOASTAL-3 topline readout for navacaprant in MDD, expected in Q2 2026 and reaffirmed on May 7 as occurring this quarter. The setup is highly binary because KOASTAL-1 already failed, but the stock is depressed near $1.83, cash runway extends into Q3 2027, and a positive surprise could trigger a sharp rerating as the market has low expectations for navacaprant. The most actionable window is late May through late June 2026, centered on the likely readout period rather than secondary H2 pipeline events.

Neumora Therapeutics is a clinical-stage neuroscience company whose near-term valuation is dominated by one event: the joint topline readout from the Phase 3 KOASTAL-2 and KOASTAL-3 studies of navacaprant in major depressive disorder. Management reiterated on May 7, 2026 that both studies are fully enrolled, include more than 400 patients each, and remain on track for a joint readout in Q2 2026. That makes this the clearest unresolved catalyst for the stock. The investment case is not straightforwardly bullish. Navacaprant already failed KOASTAL-1 in January 2025, which severely damaged confidence in the program and explains why NMRA trades at a deeply compressed valuation. The company subsequently optimized KOASTAL-2 and KOASTAL-3 and increased enrollment, including pre-specified analyses tied to patients enrolled after those changes. If the upcoming readout is positive, investors are likely to view it as a genuine resurrection of the MDD thesis and the beginning of a possible regulatory path. If negative, the lead program likely loses most remaining strategic value. That asymmetry is what makes NMRA interesting as an event-driven setup. The market cap is only about $334 million, the stock is trading below many analyst targets, and sentiment remains skeptical after the prior failure and broader KOR-class doubts. Yet Neumora still has $147.1 million in cash as of March 31, 2026, with runway into Q3 2027, so the company is not forced into an immediate pre-catalyst financing overhang. That matters because it allows the Phase 3 readout to remain the dominant driver rather than balance-sheet stress. Secondary programs such as NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia, and NMRA-215 in obesity add optionality later in 2026, but they are not the next catalyst and should not dilute focus from KOASTAL-2/3. For the coming weeks, NMRA should be viewed as a high-risk binary clinical readout trade. If the data are favorable, the stock could reprice rapidly toward prior 2026 highs and potentially beyond as investors rebuild probability of success and assign renewed value to navacaprant. If the data disappoint, downside remains substantial. The likely upside move, if it comes, should be abrupt rather than gradual.